about
Progress of small molecular inhibitors in the development of anti-influenza virus agents.Influenza virus-induced lung inflammation was modulated by cigarette smoke exposure in mice.Continuing challenges in influenza.Antivirals in seasonal and pandemic influenza--future perspectives.The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threatTropism of avian influenza A (H5N1) virus to mesenchymal stem cells and CD34+ hematopoietic stem cells.Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy.The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals.New treatments for influenzaProstaglandin E2 induction during mouse adenovirus type 1 respiratory infection regulates inflammatory mediator generation but does not affect viral pathogenesis.Vitamin D status and acute respiratory infection: cross sectional results from the United States National Health and Nutrition Examination Survey, 2001-2006.Macrophage Polarization in Virus-Host InteractionsNADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in MiceEicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.Kolaviron Improves Morbidity and Suppresses Mortality by Mitigating Oxido-Inflammation in BALB/c Mice Infected with Influenza VirusThe cytokine storm of severe influenza and development of immunomodulatory therapyIntranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection.Short-Term Heat Shock Affects Host-Virus Interaction in Mice Infected with Highly Pathogenic Avian Influenza Virus H5N1Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction.The inflammatory response triggered by Influenza virus: a two edged sword.Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.[Influenza and secondary bacterial infections: threats and treatments].Targeting host calpain proteases decreases influenza A virus infection.Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.Simvastatin modulates cellular components in influenza A virus-infected cells.Enterococcus faecalis FK-23 affects alveolar-capillary permeability to attenuate leukocyte influx in lung after influenza virus infection.Mechanisms of action and efficacy of statins against influenza.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Surviving Deadly Lung Infections: Innate Host Tolerance Mechanisms in the Pulmonary System.Viral Sepsis in Children
P2860
Q30234943-1678E26F-57F8-4AD1-A755-A98C32DA7E89Q30358340-38F55A75-1C56-4C7D-A42D-C7EC42BA7A84Q30363190-D7CF46C9-ED12-4C30-A12D-81B4A80BB8F2Q30425358-6AF69305-F8A0-482B-A1BF-6DA5A1AEA2E4Q30426929-DB98A02E-04FA-405E-9CCD-0FCBBF33A78EQ33412132-F872F5BA-422D-4122-B937-035E226A3CAAQ34131746-8BF164C1-3867-4AF0-9E95-CC307172540EQ34388075-4581ABF1-8ED6-4C33-8960-F7D693BA62FFQ34413797-4AC21414-11A2-4CC1-92E0-16286E15A833Q35023278-48A389D9-33A1-4099-968D-0D2754C86855Q35227910-78479A0F-56AE-4338-AA0E-A119B4BCBB36Q35882034-FDB4E758-36E3-49D5-9ABF-4418CAFB19BEQ35934016-ABB68242-D0E3-47BB-82BB-4B76174C3E9CQ35994233-A597F5AC-8D00-4DCF-86AE-D82853670AD8Q36030321-32F6FD77-3ACE-4DF3-91C6-32F851237156Q36459143-7DA4D38D-B993-4B76-8246-6A097BD73ED1Q36736751-BFF2A95B-B949-4FC6-9F74-6E0A93E62AB5Q37004838-205FBA42-E7E8-4589-B97B-9D4DBBA63F9FQ38122283-93DB0B6E-FC3D-4164-9CD8-3BD81891E766Q38981754-0AA0A437-0EA8-443C-8146-1F70999AD403Q39279748-63245EA9-91E2-476E-A6FE-D8372C9F2EB1Q40112217-12478D54-6F76-4CFC-8725-9D5A211BEBD0Q40160725-F36066D9-59D3-40C9-A789-09D0D34E6CA7Q40839491-D553C000-3B90-4500-B967-EA51FA493BF1Q40874583-2ACE39BF-DD2D-4F36-A3DC-1422C9B7EF42Q41274980-4DB09D8F-A49B-42F4-A369-E981D4D7FFD3Q41366819-9377FBFD-B28B-4005-B888-32AD59429D38Q42177559-36662F3D-AC79-4885-83E3-9B73882810B7Q47549703-039CF4C9-4BC0-402B-802C-B64ABC82AD0FQ55514867-48F0B643-7DC3-4569-8B2E-A3EC1F00C5BCQ57019179-F5C2B7A5-E45A-4272-AFBF-3FCB02A88588
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunomodulatory therapy for severe influenza.
@en
Immunomodulatory therapy for severe influenza.
@nl
type
label
Immunomodulatory therapy for severe influenza.
@en
Immunomodulatory therapy for severe influenza.
@nl
prefLabel
Immunomodulatory therapy for severe influenza.
@en
Immunomodulatory therapy for severe influenza.
@nl
P2860
P356
P1476
Immunomodulatory therapy for severe influenza.
@en
P2093
Ilyse Darwish
W Conrad Liles
P2860
P304
P356
10.1586/ERI.11.56
P577
2011-07-01T00:00:00Z